Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Erratum in: Blood. 2018 Sep 27;132(13):1461.

2.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ.

J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17.

PMID:
26282654
3.

Advances in the pathogenesis and diagnosis of multiple myeloma.

Chesi M, Bergsagel PL.

Int J Lab Hematol. 2015 May;37 Suppl 1:108-14. doi: 10.1111/ijlh.12360. Review.

PMID:
25976968
4.

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.

Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA.

Haematologica. 2017 Sep;102(9):1617-1625. doi: 10.3324/haematol.2017.163766. Epub 2017 May 26.

5.

Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.

Ryland GL, Jones K, Chin M, Markham J, Aydogan E, Kankanige Y, Caruso M, Guinto J, Dickinson M, Prince HM, Yong K, Blombery P.

J Clin Pathol. 2018 Oct;71(10):895-899. doi: 10.1136/jclinpath-2018-205195. Epub 2018 May 14.

PMID:
29760015
6.

Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms.

Hoang PH, Dobbins SE, Cornish AJ, Chubb D, Law PJ, Kaiser M, Houlston RS.

Leukemia. 2018 Nov;32(11):2459-2470. doi: 10.1038/s41375-018-0103-3. Epub 2018 Apr 9.

PMID:
29654271
7.

Multiple myeloma clonal evolution in homogeneously treated patients.

Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M, Munshi N, Avet-Loiseau H.

Leukemia. 2018 Jun 12. doi: 10.1038/s41375-018-0153-6. [Epub ahead of print]

PMID:
29895955
8.

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.

Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ.

Oncotarget. 2017 Apr 25;8(17):27854-27867. doi: 10.18632/oncotarget.15718.

9.

Multiple Myeloma Genomics: A Systematic Review.

Weaver CJ, Tariman JD.

Semin Oncol Nurs. 2017 Aug;33(3):237-253. doi: 10.1016/j.soncn.2017.05.001. Epub 2017 Jul 18. Review.

PMID:
28729121
10.

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.

White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH.

Blood Cancer J. 2018 Mar 21;8(3):35. doi: 10.1038/s41408-018-0062-y.

11.

Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.

Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Nakazawa N, Taniwaki M, Yawata Y, Ueki A.

Int J Oncol. 1999 Dec;15(6):1205-12.

PMID:
10568829
12.

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.

McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C.

Sci Transl Med. 2015 Apr 15;7(283):283ra54. doi: 10.1126/scitranslmed.aaa1408.

13.

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.

Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, Patel K, Umbricht C, Zeiger M, Kebebew E, Sherman E, Ghossein R, Fagin JA, Chan TA.

Cancer Cell. 2018 Aug 13;34(2):256-270.e5. doi: 10.1016/j.ccell.2018.07.002.

PMID:
30107176
14.

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.

Shi J, Hua X, Zhu B, Ravichandran S, Wang M, Nguyen C, Brodie SA, Palleschi A, Alloisio M, Pariscenti G, Jones K, Zhou W, Bouk AJ, Boland J, Hicks B, Risch A, Bennett H, Luke BT, Song L, Duan J, Liu P, Kohno T, Chen Q, Meerzaman D, Marconett C, Laird-Offringa I, Mills I, Caporaso NE, Gail MH, Pesatori AC, Consonni D, Bertazzi PA, Chanock SJ, Landi MT.

PLoS Med. 2016 Dec 6;13(12):e1002162. doi: 10.1371/journal.pmed.1002162. eCollection 2016 Dec.

15.

Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma.

Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, González-García I, Brieva JA, Dopazo J, Siebert R, Calasanz MJ, Cigudosa JC.

Haematologica. 2006 Feb;91(2):184-91.

16.

Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.

Salloum R, McConechy MK, Mikael LG, Fuller C, Drissi R, DeWire M, Nikbakht H, De Jay N, Yang X, Boue D, Chow LML, Finlay JL, Gayden T, Karamchandani J, Hummel TR, Olshefski R, Osorio DS, Stevenson C, Kleinman CL, Majewski J, Fouladi M, Jabado N.

Acta Neuropathol Commun. 2017 Oct 30;5(1):78. doi: 10.1186/s40478-017-0479-8.

17.

Loss of FAM46C Promotes Cell Survival in Myeloma.

Zhu YX, Shi CX, Bruins LA, Jedlowski P, Wang X, Kortüm KM, Luo M, Ahmann JM, Braggio E, Stewart AK.

Cancer Res. 2017 Aug 15;77(16):4317-4327. doi: 10.1158/0008-5472.CAN-16-3011. Epub 2017 Jun 15.

18.

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ.

Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11.

19.

Identification of driver copy number alterations in diverse cancer types and application in drug repositioning.

Zhou W, Zhao Z, Wang R, Han Y, Wang C, Yang F, Han Y, Liang H, Qi L, Wang C, Guo Z, Gu Y.

Mol Oncol. 2017 Oct;11(10):1459-1474. doi: 10.1002/1878-0261.12112. Epub 2017 Aug 3.

20.

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.

McFadden DG, Politi K, Bhutkar A, Chen FK, Song X, Pirun M, Santiago PM, Kim-Kiselak C, Platt JT, Lee E, Hodges E, Rosebrock AP, Bronson RT, Socci ND, Hannon GJ, Jacks T, Varmus H.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6409-E6417. Epub 2016 Oct 4.

Supplemental Content

Support Center